Results 241 to 250 of about 66,322 (262)

NTRK fusion-positive cancers and TRK inhibitor therapy

Nature Reviews Clinical Oncology, 2018
Emiliano Cocco, Maurizio Scaltriti, Alexander Drilon   +2 more
exaly  

The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy

Nature Reviews Cancer, 2019
Jonathan J Havel, Diego Chowell, Timothy A Chan   +2 more
exaly  

Balance between Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases

Cardiology, 2014
Emre Yalcinkaya, Murat Celik
openaire   +1 more source

Tissue inhibitors of matrix metalloproteinases

2011
openaire   +1 more source

The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy

Nature Reviews Cancer, 2008
Ludger Hengst, Joyce M Slingerland
exaly  

Appraising iniparib, the PARP inhibitor that never was—what must we learn?

Nature Reviews Clinical Oncology, 2013
Joaquin Mateo, Michael Ong, David S P Tan   +2 more
exaly  

The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial

Lancet, The, 2012
Michael R Zile, Adriaan A Voors, Milton Packer   +2 more
exaly  

Tissue inhibitors of matrix metalloproteinases

2006
openaire   +1 more source

Discovery and development of sorafenib: a multikinase inhibitor for treating cancer

Nature Reviews Drug Discovery, 2006
Brian Schwartz
exaly  

Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study

Lancet, The, 2013
Marina Cuchel, Dirk J Blom, A David Marais   +2 more
exaly